Arcutis Biotherapeutics, Inc.
ARQT
$31.19
$1.234.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 313.93M | 259.47M | 208.82M | 166.54M | 110.71M |
| Total Other Revenue | 4.00M | 4.00M | 4.00M | 30.00M | 28.00M |
| Total Revenue | 317.93M | 263.47M | 212.82M | 196.54M | 138.71M |
| Cost of Revenue | 31.91M | 28.73M | 24.70M | 19.13M | 14.47M |
| Gross Profit | 286.02M | 234.74M | 188.12M | 177.41M | 124.24M |
| SG&A Expenses | 253.18M | 249.60M | 238.60M | 229.39M | 220.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 356.18M | 349.30M | 334.12M | 324.94M | 320.64M |
| Operating Income | -38.25M | -85.84M | -121.30M | -128.40M | -181.93M |
| Income Before Tax | -43.30M | -92.33M | -129.12M | -139.39M | -195.19M |
| Income Tax Expenses | 1.02M | 944.00K | 602.00K | 647.00K | 349.00K |
| Earnings from Continuing Operations | -44.32 | -93.27 | -129.72 | -140.04 | -195.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.32M | -93.27M | -129.72M | -140.04M | -195.54M |
| EBIT | -38.25M | -85.84M | -121.30M | -128.40M | -181.93M |
| EBITDA | -33.68M | -80.57M | -116.43M | -126.29M | -179.90M |
| EPS Basic | -0.35 | -0.74 | -1.04 | -1.16 | -1.79 |
| Normalized Basic EPS | -0.22 | -0.46 | -0.65 | -0.72 | -1.12 |
| EPS Diluted | -0.35 | -0.74 | -1.04 | -1.16 | -1.79 |
| Normalized Diluted EPS | -0.22 | -0.46 | -0.65 | -0.72 | -1.12 |
| Average Basic Shares Outstanding | 505.58M | 502.25M | 498.74M | 483.75M | 451.41M |
| Average Diluted Shares Outstanding | 510.84M | 502.25M | 498.74M | 483.75M | 451.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |